Compare · PDEX vs RMD
PDEX vs RMD
Side-by-side comparison of Pro-Dex Inc. (PDEX) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PDEX and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $34.07B, about 175.6x PDEX ($194.1M).
- RMD has been more active in the news (9 items in the past 4 weeks vs 2 for PDEX).
- RMD has more recent analyst coverage (25 ratings vs 0 for PDEX).
- Company
- Pro-Dex Inc.
- ResMed Inc.
- Price
- -
- -
- Market cap
- $194.1M
- $34.07B
- 1M return
- -13.35%
- -
- 1Y return
- +136.75%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 2
- 9
- Recent ratings
- 0
- 25
Pro-Dex Inc.
Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and maxocranial facial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company was founded in 1978 and is headquartered in Irvine, California.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest PDEX
- SEC Form DEFA14A filed by Pro-Dex Inc.
- SEC Form DEF 14A filed by Pro-Dex Inc.
- Pro-Dex Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Chief Executive Officer Van Kirk Richard Lee Jr sold $45,412 worth of shares (765 units at $59.36) as part of a pre-agreed trading plan, decreasing direct ownership by 0.96% to 79,228 units (SEC Form 4)
- Chief Executive Officer Van Kirk Richard Lee Jr sold $1,165,290 worth of shares (19,235 units at $60.58) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 79,993 units (SEC Form 4)
- Chief Financial Officer Charlton Alisha sold $140,983 worth of shares (2,300 units at $61.30), decreasing direct ownership by 10% to 21,870 units (SEC Form 4)
- Pro-Dex Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-K filed by Pro-Dex Inc.
- Pro-Dex, Inc. Announces Fiscal 2026 Fourth Quarter and Full-Year Results
- Pro-Dex Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
Latest RMD
- SEC Form 4 filed by ResMed Inc.
- SEC Form DEFA14A filed by ResMed Inc.
- SEC Form DEF 14A filed by ResMed Inc.
- Amendment: SEC Form 4 filed by Chairman and CEO Farrell Michael J.
- Chief Product Officer Leong Justin was granted 6,461 units of ResMed Common Stock, increasing direct ownership by 22% to 35,489 units (SEC Form 4)
- Global General Counsel Rider Michael J was granted 3,230 units of ResMed Common Stock, increasing direct ownership by 34% to 12,718 units (SEC Form 4)
- Chairman and CEO Farrell Michael J. was granted 13,547 units of ResMed Common Stock, increasing direct ownership by 3% to 479,803 units (SEC Form 4)
- Chief Financial Officer Bloomer Aaron was granted 9,072 units of ResMed Common Stock (SEC Form 4)
- Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
- ResMed upgraded by RBC Capital Mkts with a new price target